(rivaroxaban)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Management of bleeding - Registry data
Last updated : 08/25/2025
Beyer-Westendorf et al (2015) analyzed the rates, management, and outcome of XARELTO-related bleeding using data from a prospective, noninterventional oral anticoagulation registry.1
- Between October 1, 2011, and December 31, 20131:
1776
patients were enrolled in the registry
42.9%
of patients (n=762) reported 1082 bleeding events during/within 3 days after the last intake of XARELTO
6.1%
of these events were classified as major, and PCC (n=3), FFP (n=3), and PCC/FFP were used in 9 of these cases.
- Of the 6 patients who received PCC, only 1 case showed significant improvement (corrected INR from 4.0 to 1.4, PT ratio from 17% to 62%, and aPTT from 65.8 to 37.8 seconds).1
- Slight changes were observed in 3 patients, of whom 2 had received the last intake of XARELTO >24 hours before admission.1
- One patient died as a result of pneumonia and septic shock on day 16.1
aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; INR, international normalized ratio; PCC, prothrombin complex concentrate; PT, prothrombin time.
Reference
Show Hide
1. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-962.
